EQRx Temettü

Temettü kriter kontrolleri 0/6

EQRx does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-0.06%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.06%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if EQRX's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if EQRX's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

EQRx Piyasaya Karşı Temettü Getirisi

EQRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (EQRX)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (EQRX) (3 yıla kadar)	0%

Önemli Temettü: Unable to evaluate EQRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate EQRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate EQRX's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as EQRX has not reported any payouts.

EQRx Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

EQRx, Inc. Files Form 15

EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

New minor risk - Share price stability

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the Uk's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-Small Cell Lung Cancer

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

High number of new and inexperienced directors

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

EQRx GAAP EPS of -$0.17 beats by $0.03

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

EQRx, Inc., Annual General Meeting, Sep 30, 2022

Eqrx Announces Acceptance of Marketing Authorization Application by U.K.'s Medicines and Healthcare Products Regulatory Agency for Aumolertinib

EQRx, Inc. Announces New Data for Lead Oncology Programs in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

High number of new and inexperienced directors

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin

EQRx Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

EQRx, Inc. Files Form 15

EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

New minor risk - Share price stability

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the Uk's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-Small Cell Lung Cancer

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

High number of new and inexperienced directors

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

&nbsp;EQRx GAAP EPS of -$0.17 beats by $0.03

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

EQRx, Inc., Annual General Meeting, Sep 30, 2022

Eqrx Announces Acceptance of Marketing Authorization Application by U.K.'s Medicines and Healthcare Products Regulatory Agency for Aumolertinib

EQRx, Inc. Announces New Data for Lead Oncology Programs in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

High number of new and inexperienced directors

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin

EQRx GAAP EPS of -$0.17 beats by $0.03